CLINICAL_TRIALS
trial_result
· 2025-06-18
Clinical Trial Update: Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma [Phase 2]
Summary
Verrica's VP-315 completed an open-label Phase 2 proof-of-concept study in basal cell carcinoma, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Verrica Pharmaceuticals Inc. | Conditions: Basal Cell Carcinoma, Skin Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-06-18